All In Biotech

NDA 018086 · Bausch and Lomb INC

Timoptic

Timolol Maleate · Ophthalmic

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Nov 17, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1978

Aug 17, 1978

Approved uses

1

Original approval plus efficacy supplements

Registered trials

306

98 Phase 3, 14 recruiting

FAERS reports

9,481

4,819 serious, 575 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 4, 2025.

INDICATIONS AND USAGE Timolol Maleate Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

Mechanism: Mechanism of Action Timolol maleate is a beta 1 and beta 2 (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity. Beta-adrenergic receptor blockade reduces cardiac output in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function. Beta-adrenergic...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 17, 1978 Original approval · Type 1 - New Molecular Entity · priority review
2 products under this application
  • TIMOPTIC · TIMOLOL MALEATE EQ 0.5% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT1
  • TIMOPTIC · TIMOLOL MALEATE EQ 0.25% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription · TE AT1

Clinical trials

Interventional ClinicalTrials.gov studies with "Timolol" as an intervention, any sponsor and status, largest first.

All 306 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • treatment failure1,009
  • drug ineffective668
  • eye pain503
  • fatigue502
  • eye irritation432
  • dizziness363
  • diarrhoea341
  • nausea337
  • vision blurred316
  • dyspnoea309
  • headache302
  • off label use298

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004250
2005287
2006250
2007239
2008218
2009213
2010290
2011278
2012385
2013166
2014205
2015337
2016384
2017423
2018435
2019505
20201,537
2021474
2022500
2023568
2024560
2025600
2026376

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Bausch and Lomb INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.